Very average results. Don't fall into the trap of being mislead by management.
Clinical efficacy is ambigious at best. Anyone emailed management to find out what "reduction in cancer burden" means? No disease progression sounds like stable disease to me.
The phase 1b clinical trial was not able to identify how PTX100 demonstrated clinical efficacy in some patients. If the expansion cohort is anything like the phase 1b trial, PTX investors will now have to wait >2-years for PTX100 data. PTX100 phase 1b trial initiated 11/07/2019 and completed 27/07/21 = >2-years. If you check clinicaltrials website, there are many PTCL trials underway, indicating that trial advancement may be even slower.
https://clinicaltrials.gov/ct2/results?cond=PTCL&term=&cntry=&state=&city=&dist=While not disclosed in the announcement, the standard of care for PTCL over the last 30-years has been cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) with or without additional etoposide (CHOEP) (link below). As of 2016, these were some of the drugs targeting PTCL with poor to average response rates.
https://journals.lww.com/hemasphere/fulltext/2020/10000/controversies_in_the_treatment_of_peripheral.7.aspx
Clinical and commercial risk high, potential profits low.
